Methylprednisolone and Cyclophosphamide, Alone or in Combination, in Patients with Lupus Nephritis: A Randomized, Controlled Trial

Annals of Internal Medicine

Volumn 125, Issue 7, 1996, Pages 549-557

  Gourley, Mark F ^a   Austin III, Howard A ^a   Scott, Dorothy ^a   Yarboro, Cheryl H ^a   Vaughan, Ellen M ^a   Muir, Joanne ^a   Boumpas, Dimitrios T ^a   Klippel, John H ^a   Balow, James E ^a   Steinberg, Alfred D ^a,b  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b NOBLIS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFLAMMATORY AGENT; CYCLOPHOSPHAMIDE; METHYLPREDNISOLONE;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG ADMINISTRATION; DRUG COMBINATION; FEMALE; FOLLOW UP; HUMAN; LIFE TABLE; LUPUS ERYTHEMATOSUS NEPHRITIS; MALE; MIDDLE AGED; RANDOMIZED CONTROLLED TRIAL; REMISSION;

ADULT; ANTI-INFLAMMATORY AGENTS; CYCLOPHOSPHAMIDE; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; LIFE TABLES; LUPUS NEPHRITIS; MALE; METHYLPREDNISOLONE; MIDDLE AGED; REMISSION INDUCTION;

EID: 0030268581     PISSN: 00034819     EISSN: None     Source Type: Journal    
DOI: 10.7326/0003-4819-125-7-199610010-00003     Document Type: Article

References (33)

1. Carette S, Klippel JH, Decker JL, Austin HA 3d, Plotz PH, Steinberg AD, et al. Controlled studies of oral immunosuppressive drugs in lupus nephritis. A long-term follow-up. Ann Intern Med. 1983;99:1-8.
2. Steinberg AD, Steinberg SC. Long-term preservation of renal function in patients with lupus nephritis receiving treatment that includes cyclophosphamide versus those treated with prednisone only. Arthritis Rheum. 1991;34: 945-50.
3. Boumpas DT, Austin HA 3d, Vaughan EM, Klippel JH, Steinberg AD, Yarboro CH, et al. Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis. Lancet. 1992; 340:741-5.
4. Steinberg AD, Decker JL. A double-blind controlled trial comparing cyclophosphamide, azathioprine and placebo in the treatment of lupus glomerulonephritis. Arthritis Rheum. 1974;17:923-37.
5. Dinant HJ, Decker JL, Klippel JH, Balow JE, Plotz PH, Steinberg AD. Alternative modes of cyclophosphamide and azathioprine therapy in lupus nephritis. Ann Intern Med. 1983;96(6 Pt 1):728-36.
6. Austin HA 3d, Klippel JH, Balow JE, le Riche NG, Steinberg AD, Plotz PH, et al. Therapy of lupus nephritis. Controlled trial of prednisone and cytotoxic drugs. N Engl J Med. 1986;314:614-9.
7. Boumpas DT, Yamada H, Patronas NJ, Scott D, Klippel JH, Balow JE. Pulse cyclophosphamide for severe neuropsychiatric lupus. Q J Med. 1991;81: 975-84.
8. Donadio JV Jr, Holley KE, Ferguson RH, Ilstrup DM. Treatment of diffuse proliferative lupus nephritis with prednisone and combined prednisone and cyclophosphamide. N Engl J Med. 1978;299:1151-5.
9. Liebling MR, McLaughlin K, Boonsue S, Kasdin J, Barnett EV. Monthly pulses of methylprednisolone in SLE nephritis. J Rheumatol. 1982;9:543-8.
10. Isenberg DA, Morrow WJ, Snaith ML. Methyl prednisolone pulse therapy in the treatment of systemic lupus erythematosus. Ann Rheum Dis. 1982;41: 347-51.
11. Steinberg AD, Kaltreider HB, Staples PJ, Goetzl EJ, Talal N, Decker JL. Cyclophosphamide in lupus nephritis: a controlled trial. Ann Intern Med. 1971;75:165-71.
12. Sztejnbok M, Stewart A, Diamond H, Kaplan D. Azathioprine in the treatment of systemic lupus erythematosus. A controlled study. Arthritis Rheum. 1971;14:639-45.
13. Cade R, Spooner G, Schlein E, Pickering M, DeQuesada A, Holcomb A, et al. Comparison of azathioprine, prednisone, and heparin alone or combined in treating lupus nephritis. Nephron. 1973;10:37-56.
14. Hahn BH, Kantor OS, Osterland CK. Azathioprine plus prednisone compared with prednisone alone in the treatment of systemic lupus erythematosus. Report of a prospective controlled trial in 24 patients. Ann Intern Med. 1975;83:597-605.
15. Cathcart ES, Idelson BA, Scheinberg MA, Couser WG. Beneficial effects of methylprednisolone "pulse" therapy in diffuse proliferative lupus nephritis. Lancet. 1976;1:163-6.
16. Bertoni M, Brugnolo F, Bertoni E, Salvadori M, Romagnani S, Emmi L. Long term efficacy of high-dose intravenous methylprednisolone pulses in active lupus nephritis. A 21-month prospective study. Scand J Rheumatol. 1993;23:82-6.
17. Kimberly RP, Lockshin MD, Sherman RL, McDougal JS, Inman RD, Christian CL. High-dose intravenous methylprednisolone pulse therapy in systemic lupus erythematosus. Am J Med 1981;70:817-24.
18. McCune WJ, Golbus J, Zeldes W, Bohlke P, Dunne R, Fox DA. Clinical and immunologic effects of monthly administration of intravenous cyclophosphamide in severe systemic lupus erythematosus. N Engl J Med. 1988;318: 1423-31.
19. Sesso R, Monteiro M, Sato E, Kirsztajn G, Silva L, Ajzen H. A controlled trial of pulse cyclophosphamide versus pulse methylprednisolone in severe lupus nephritis. Lupus. 1994;3:107-12.
20. Belmont HM, Storch M, Buyon J, Abramson S. New York University/ Hospital for Joint Diseases experience with intravenous cyclophosphamide treatment: efficacy in steroid unresponsive lupus nephritis. Lupus. 1996;4: 104-8.
21. Eiser AR, Grishman E, Dreznin S. Intravenous pulse cyclophosphamide in the treatment of type IV nephritis. Clin Nephrol. 1993;40:155-9.
22. Gelfand MC, Steinberg AD, Nagle R, Knepshield JH. Therapeutic studies in NZB-W mice. I. Synergy of azathioprine, cyclophosphamide and methylprednisolone in combination. Arthritis Rheum. 1972;15:239-46.
23. Steinberg AD, Gelfand MC, Hardin JA, Lowenthal DT. Therapeutic studies in NZB/W mice. III. Relationship between renal status and efficacy of immunosuppressive drug therapy. Arthritis Rheum. 1975;18:9-14.
24. Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1982;25:1271-7.
25. Austin HA 3d, Muenz LR, Joyce KM, Antonovych TT, Balow JE. Diffuse proliferative lupus nephritis: identification of specific pathologic features affecting renal outcome. Kidney Int. 1984;25:689-95.
26. Yarboro CH, Wesley R, Amantea MA, Klippel JH, Pucino F. Modified oral ondansetron regimen for cyclophosphamide-induced emesis in lupus nephritis patients. Ann Pharmacother. 1996;30:752-5.
27. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. Journal of the American Statistical Association. 1958;53:457-481.
28. Gehan EA. A generalized Wilcoxon test for comparing arbitrarily singly-censored samples. Biometrika. 1965;52:203-23.
29. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep. 1966;50:163-70.
30. Beneditti J, Yuen K, Young L. Life tables and survival functions. In: Dixon WJ, ed. BMDP Statistical Software. Berkeley: Univ of California Pr; 1990: 739-806.
31. Freedman MD, Schocket AL, Chapel N, Gerber JG. Anaphylaxis after intravenous methylprednisolone administration. JAMA. 1981;245:607-8.
32. Massardo L, Jacobelli S, Leissner M, Gonzalez M, Villarroel L, Rivero S. High-dose intravenous methylprednisolone therapy associated with osteonecrosis in patients with systemic lupus erythematosus. Lupus. 1992;1:401-5.
33. Wysenbeek AJ, Leibovici L, Zoldan J. Acute central nervous system complications after pulse steroid therapy in patients with systemic lupus erythematosus. J Rheumatol. 1990;17:1695-6.